Treatment efficacy of ramucirumab-containing chemotherapy in patients with alpha-fetoprotein producing gastric cancer

[1]  Tianhua Zhou,et al.  Whole-exome sequencing of alpha-fetoprotein producing gastric carcinoma reveals genomic profile and therapeutic targets , 2021, Nature Communications.

[2]  Xiaoli Ma,et al.  The clinicopathological features and prognosis of serum AFP positive gastric cancer: a report of 16 cases. , 2020, International journal of clinical and experimental pathology.

[3]  Xiubao Ren,et al.  Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer , 2019, Translational oncology.

[4]  L. Shen,et al.  Hepatoid adenocarcinoma of the stomach: a unique subgroup with distinct clinicopathological and molecular features , 2019, Gastric Cancer.

[5]  M. Kudo,et al.  Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[6]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[7]  G. Beretta,et al.  Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study , 2018, Targeted Oncology.

[8]  L. Shen,et al.  Predictive and prognostic value of serum AFP level and its dynamic changes in advanced gastric cancer patients with elevated serum AFP , 2018, World journal of gastroenterology.

[9]  M. Shimizu,et al.  Effective Treatment of Cytotoxic Agent Refractory Alpha-Fetoprotein-Producing Gastric Cancer with Ramucirumab: a Case Report and Review of the Literature , 2019, Journal of Gastrointestinal Cancer.

[10]  T. Yoshikawa,et al.  Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[11]  M. Ikegami,et al.  Significant response to ramucirumab monotherapy in chemotherapy-resistant recurrent alpha-fetoprotein-producing gastric cancer: A case report. , 2017, Oncology letters.

[12]  Y. Bozkaya,et al.  Clinicopathological and prognostic characteristics in patients with AFP-secreting gastric carcinoma. , 2017, Molecular and clinical oncology.

[13]  J. Yoshizawa,et al.  Gastric hepatoid adenocarcinoma resulting in a spontaneous gastric perforation: a case report and review of the literature , 2017, BMC Cancer.

[14]  Lizong Shen,et al.  Clinicopathologic and prognostic characteristics of alpha-fetoprotein–producing gastric cancer , 2017, Oncotarget.

[15]  S. Qin,et al.  Successful multimodal therapy for an α-fetoprotein-producing gastric cancer patient with simultaneous liver metastases. , 2015, Oncology letters.

[16]  J. Zucman‐Rossi,et al.  Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. , 2015, Gastroenterology.

[17]  S. Lilly,et al.  Hepatoid Adenocarcinoma of the Gall Bladder-A Rare Variant. , 2015, Journal of clinical and diagnostic research : JCDR.

[18]  Joon-Oh Park,et al.  Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. , 2015, The Lancet. Oncology.

[19]  Naotoshi Sugimoto,et al.  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[20]  C. Fuchs,et al.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial , 2014, The Lancet.

[21]  T. Goi,et al.  Five-Year Survival of Alpha-Fetoprotein-Producing Gastric Cancer with Synchronous Liver Metastasis: A Case Report , 2013, Journal of gastric cancer.

[22]  K. Fukuda,et al.  [Retrospective analysis concerning AFP-producing gastric cancer]. , 2013, Gan to kagaku ryoho. Cancer & chemotherapy.

[23]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[24]  T. Gotoda,et al.  Histologic and Immunohistochemical Analyses of &agr;-Fetoprotein—Producing Cancer of the Stomach , 2012, The American journal of surgical pathology.

[25]  Mengtao Zhou,et al.  Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and α-fetoprotein expression status , 2011, Medical oncology.

[26]  Takefumi Nakamura,et al.  [A case of AFP-producing gastric cancer resected after efficient S-1/CDDP combination chemotherapy]. , 2011, Gan to kagaku ryoho. Cancer & chemotherapy.

[27]  M. Rugge,et al.  Hepatoid Adenocarcinoma of the Colon: What Should We Target? , 2011, Pathology & Oncology Research.

[28]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[29]  H. Katai,et al.  Long‐term results of gastrectomy for α‐fetoprotein‐producing gastric cancer , 2010, The British journal of surgery.

[30]  A. Reiter,et al.  Hepatoid Adenocarcinoma – Review of the Literature Illustrated by a Rare Case Originating in the Peritoneal Cavity , 2010, Oncology Research and Treatment.

[31]  M. Moriyama,et al.  [A case of alpha-fetoprotein-producing gastric cancer with hepatic metastasis successfully treated with combination chemotherapy]. , 2008, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.

[32]  Jin Woo Kim,et al.  EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. , 2008, Cancer research.

[33]  K. Notohara,et al.  Hepatoid carcinoma of the pancreas producing protein induced by vitamin K absence or antagonist II (PIVKA-II) and α-fetoprotein (AFP) , 2006, Journal of Gastroenterology.

[34]  M. Ichinose,et al.  A case of primary lung cancer producing alpha-fetoprotein. , 2004, Canadian respiratory journal.

[35]  S. Kitano,et al.  AFP-Producing Gastric Carcinoma: Multivariate Analysis of Prognostic Factors in 270 Patients , 2003, Oncology.

[36]  H. Fujii,et al.  Evaluation of VEGF and VEGF-C expression in gastric cancer cells producing alpha-fetoprotein. , 2003, Journal of gastroenterology.

[37]  H. Fujii,et al.  Evaluation of VEGF and VEGF-C expression in gastric cancer cells producing α-fetoprotein , 2003, Journal of Gastroenterology.

[38]  J. Shimazaki,et al.  Hepatoid adenocarcinoma of the stomach , 2001, Gastric Cancer.

[39]  N. Koide,et al.  α-Fetoprotein–producing gastric cancer: histochemical analysis of cell proliferation, apoptosis, and angiogenesis , 1999, American Journal of Gastroenterology.

[40]  N. Nagasue,et al.  Clinicopathologic features and long-term results of alpha-fetoprotein-producing gastric cancer. , 1990, The American journal of gastroenterology.

[41]  X. L. Wang.  [Hepatoid adenocarcinoma of the stomach]. , 1988, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[42]  A. Ajdukiewicz,et al.  CONCANAVALIN‐A‐AFFINITY MOLECULAR HETEROGENEITY OF HUMAN HEPATOMA AFP AND CORD‐SERUM AFP a , 1983, Annals of the New York Academy of Sciences.

[43]  B. No̸rgaard-Pedersen,et al.  Serum alpha-foetoprotein as a marker for endodermal sinus tumour (yolk sac tumour) or a vitelline component of "teratocarcinoma". , 2009, Acta pathologica et microbiologica Scandinavica. Section A, Pathology.

[44]  T. Waldmann,et al.  Serum alpha-fetoprotein in patients with neoplasms of the gastrointestinal tract. , 1975, Cancer research.

[45]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .

[46]  A. Fondimare,et al.  [Existence of alpha feto protein during gastric-origin secondary cancer of the liver]. , 1970, La Presse medicale.

[47]  C G BERGSTRAND,et al.  Demonstration of a new protein fraction in serum from the human fetus. , 1956, Scandinavian journal of clinical and laboratory investigation.